Add like
Add dislike
Add to saved papers

Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.

GOALS: We categorized gastric cancers into four types of tumor immune microenvironment based on PD-L1 expression and tumor-infiltrating lymphocytes (TILs) to analyze clinicopathologic characteristics and recommend an immunotherapy-targetable subgroup.

PROCEDURES: Formalin-fixed, paraffin-embedded tissue samples of randomly selected gastric adenocarcinoma (n=479) were obtained and arrayed using a tissue-arraying instrument. Immunohistochemical stains for PD-L1, PD-1, and CD8 were performed and evaluated in addition to microsatellite instability, EBV infection, and HER-2 analyses.

RESULTS: Tumor microenvironment immune type (TMIT) I (both PD-L1-positive tumor cells & CD8-high TILs) and type III (PD-L1-positive tumor cells & CD8-low TILs) showed the best and worse prognosis, respectively. PD-L1 expression was significantly associated with Epstein-Barr virus infection ( p <0.001) and microsatellite instability status ( p <0.001). PD-L1 immunoreactivity was positively correlated with TILs having CD8 or PD-1 overexpression.

CONCLUSIONS: TMIT I subgroup showed more patent CD8/PD-L1/PD-1 signaling pathway compared to other types. Therefore, TMIT I subgroup is a good candidate to predict effective response rate for immune checkpoint blockers. Such stratification of gastric cancers into four types can be used to predict the prognosis of patients and determine the immunotherapy-targetable subgroup.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app